3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Lymphoma, T-Cell, Peripheral
5
Lymphoma, T-Cell, Cutaneous
3
Lymphoma, T-Cell
3
Lymphoma
2
Immunoblastic Lymphadenopathy
2
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Mycosis Fungoides
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Leukemia, Prolymphocytic, T-Cell
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Interventions
Gemcitabine
113
130-nm albumin-bound paclitaxel
64
Albumin-Bound Paclitaxel
43
Fluorouracil
37
Magnetic Resonance Spectroscopy
35
pembrolizumab
34
Irinotecan
34
Taxes
33
Specimen Handling
33
Leucovorin
33
Oxaliplatin
31
Biopsy
22
Cyclophosphamide
21
Nivolumab
18
fludarabine
16
Radiosurgery
16
Cisplatin
16
Drug Therapy
15
Capecitabine
12
folfirinox
11
durvalumab
11
Radiotherapy
11
irinotecan sucrosofate
10
Ipilimumab
10
Cetuximab
10
Carboplatin
10
Blood Specimen Collection
10
olaparib
9
Standard of Care
9
dehydroftorafur
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pancreatic Neoplasms
×
romidepsin
×
1 year
×
Clear all
NCT04257448
2025-09-30
SEPION
GWT-TUD GmbH
Phase 1/2
Completed
75 enrolled